Table 3.
Total IgG prevalence of each recombinant PvRBP protein including predicted B-cell epitope domain
| Antigen (PVX_) | No. of patients samples (n) |
95% Cib (%) | MFIc | No. of healthy samples (n) |
95% CI (%) | MFI | P-valuee | Features/Structures | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Posit. | Neg. | Total (%)a | Posit. | Neg. | Total (%)d | |||||||
| 098585-1 | 10 | 6 | 16 (62.5) | 38.6-81.5 | 6,429 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,139 | 0.0013 | Repeat sequence |
| 098585-2 | 8 | 8 | 16 (50.0) | 28.0-72.0 | 5,480 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 2,943 | 0.0016 | C-terminal |
| 098582-1 | 6 | 10 | 16 (37.5) | 18.5-61.4 | 5,806 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,275 | 0.0011 | N-terminal |
| 098582-2 | 10 | 6 | 16 (62.5) | 38.6-81.5 | 6,566 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,181 | 0.0004 | Coiled coil |
| 125738-1 | 11 | 5 | 16 (68.8) | 44.4-85.8 | 9,242 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,970 | 0.0002 | Coiled coil |
| 125738-2 | 11 | 5 | 16 (68.8) | 44.4-85.8 | 10,280 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,741 | 0.0003 | C-terminal |
| 121920-1 | 11 | 5 | 16 (68.8) | 44.4-85.8 | 11,283 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 4,628 | 0.0013 | N-terminal |
| 121920-2 | 11 | 5 | 16 (68.8) | 44.4-85.8 | 9,232 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,863 | 0.0007 | Low complexity |
| 121920-3 | 11 | 5 | 16 (68.8) | 44.4-85.8 | 8,821 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,010 | 0.0005 | Repeat sequence |
| 121920-4 | 6 | 10 | 16 (37.5) | 18.5-61.4 | 6,947 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,710 | 0.0053 | C-terminal |
| 094255-1 | 12 | 4 | 16 (75.0) | 50.5-89.8 | 13,325 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 5,163 | 0.0007 | Repeat sequence |
| 094255-2 | 8 | 8 | 16 (62.5) | 28.0-72.0 | 6,307 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,394 | 0.0011 | C-terminal |
| 090325-1 | 14 | 2 | 16 (87.5) | 64.0-96.5 | 17,597 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 6,257 | 0.0002 | N-terminal |
| 090325-2 | 9 | 7 | 16 (56.3) | 33.2-76.9 | 19,179 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 7,226 | 0.0004 | Short coiled coil |
| 090325-3 | 11 | 5 | 16 (68.8) | 44.4-85.8 | 18,615 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 6,095 | 0.0007 | C-terminal |
| 090330-1 | 13 | 3 | 16 (81.3) | 57.0-93.0 | 12,413 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 4,455 | 0.0002 | N-terminal |
| 090330-2 | 7 | 9 | 16 (43.8) | 23.1-66.8 | 12,149 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 6,072 | 0.0030 | Short coiled coil |
| 101590-1 | 9 | 7 | 16 (56.3) | 33.1-76.9 | 7,223 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,299 | 0.0005 | N-terminal |
| 116930-1 | 12 | 4 | 16 (75.0) | 50.5-89.8 | 12,407 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 4,522 | 0.0004 | Short coiled coil |
| 116930-2 | 14 | 2 | 16 (87.5) | 64.0-96.5 | 11,332 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 3,346 | 0.0005 | Repeat sequence |
| PvMSP1-19 | 4 | 0 | 4 (100.0) | 51.0-100.0 | 9,987 | 0 | 8 | 8 (100.0) | 67.6-100.0 | 1,887 | 0.0286 | |
a
Sensitivity, percentage of positives in patient samples.
b
CI, confidence intervals.
c
MFI, mean fluorescence intensity.
d
Specificity, percentage of negatives in healthy samples.
e
Differences in the total IgG prevalence for each antigen between patients and healthy individuals were calculated with Mann-Whitney U test. P<0.05 considered as statistically significant.